Waxman Quoted on Synthetic Biology

Foley Partner and chair of the Health Care Industry Team Mark Waxman was quoted in an article titled “Engineering a new business” in the December 2009 issue of Nature Biotechnology. Waxman discusses the legal and regulatory challenges facing synthetic biology, noting that the patents involved in synthetic biology intellectual property have not been tested and a number of them make some very broad claims. He adds that a consensus needs to be reached on what ought to be regulated and how, but the problem may be difficult to solve with gene synthesis.